|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
Optimizing Multi-Disciplinary Care Teams for Radiopharmaceutical Administration
|
|
Neal Shore, MD, FACS
|
| Neal Shore joins Alicia Morgans in a conversation on the multidisciplinary approach and successfully incorporating radium-223 into the treatment algorithm for men with mCRPC. |
|
|
|
|
|
|
|
|
|
|
|
|
The Correlation Between Alkaline Phosphatase Decline and Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer in the REASSURE Study
|
|
Nicholas James, MBBS, FRCP, FRCR, Ph.D.
|
| Nicholas James and Alicia Morgans discuss the relationship between alkaline phosphatase decline and OS in men with mCRPC and symptomatic bone metastases treated with radium-223 in the REASSURE study.
|
|
|
|
|
|
|
|
|
|
|
|
|
Multidisciplinary Team Approach to Treatment with Radium-223 for mCRPC
|
Brenda Martone, MSN, ANP-BC, AOCNP
Brenda Martone offers a nurse practitioner's perspective on a multidisciplinary approach used to ensure the safe and efficient administration of Radium-223 to patients with mCRPC. |
|
|
|
|
|
|
|
|
|
|
|
Optimizing the Use of Radium-223 Through Multidisciplinary Collaboration
|
Phillip J. Koo, MD, FACS
In this conversation, Alicia Morgans and Phillip Koo discuss optimizing the use of radium-223 through multidisciplinary collaboration. |
|
|
|
|
|
|
|
|
|
|
| Alkaline Phosphatase Decline and Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in the REASSURE Study
|
| Nicholas James, MBBS, FRCP, FRCR, Ph.D.
|
| Nicholas James presents the prognostic value of alkaline phosphatase decline among patients with mCRPC treated with radium-223 in the REASSURE study. |
|
|
|
|
|
| Is There Still a Role for Radium-223?
|
| Neal D. Shore, MD, FACS
|
| Neal Shore discusses the role of radium-223 in the modern treatment armamentarium. There are many ongoing trials in both the mCRPC and metastatic castration-sensitive space that will help better define the role of radium-223. |
|
|
|
|
|
|
|
|
|
|
| Targeting Prostate-Specific Membrane Antigen: Lutetium and the Next Wave of Novel Radiopharmaceuticals
|
| Shahneen Sandhu, MD, Ph.D., MBBS, FRACP
|
| Shahneen Sandhu discusses targeting PSMA, specifically lutetium and the next wave of novel radiopharmaceuticals. |
|
|
|
|
|
| Safety and Survival Outcomes in Patients With mCRPC Treated With 177Lu-PSMA After Radium-223: Interim Analysis of the RALU Study
|
| Kambiz Rahbar, MD
|
| Kambiz Rahbar discusses sequential treatment with 177Lu-PSMA after radium-223 in men with mCRPC. |
|
|
|
|
|
| Mechanisms of Resistance to Radiopharmaceuticals
|
| Johannes Czernin, MD
|
| Johannes Czernin discusses mechanisms of resistance to radiopharmaceuticals. Dr. Czernin highlighted that mutational status matters given that p53 mutations create resistance to external beam radiotherapy, and p53 loss renders prostate cancer resistant to PSMA radioligand therapy. |
|
|
|
|
|
| Is Nuclear Medicine Taking over the Treatment of Metastatic Prostate Cancer? PRLT Is Only a Tessera in the Treatment of CRPC
|
| Frederic Pouliot, MD
|
| Radioligand therapy is promising, but Dr. Pouliot poses: is it really as simple as PSMA PET positive disease = PSMA radioligand targetable = PSA response = clinical benefits?
|
|
|
|
|
|
| Is Nuclear Medicine Taking over the Treatment of Metastatic Prostate Cancer? PRLT Could Do Much More If Applied Earlier and Repetitive
|
| Christian La Fougere, MD
|
| Christian La Fougere discusses prostate radioligand therapy and its use earlier in the disease process. |
|
|
|
|
|
|
